Search Results
Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6181 pages
Showing 1951 - 2000NCI Honors Augusto Ochoa, MD, for Contributions to Community-Based Cancer Clinical Trials
The National Cancer Institute (NCI) chose Augusto Ochoa, MD, of Louisiana State University (LSU) Health, as the 2022 recipient of the Harry Hynes Award for Outstanding Contributions to Clinical Trials and Community Research. The award was presented during the NCI Community Oncology Research Program ...
Pediatric Surgeon Henri R. Ford, MD, Chosen New President-Elect of American College of Surgeons
Pediatric surgeon and surgeon-scientist Henri R. Ford, MD, MHA, FACS, FRCS, FAAP, has been chosen as President-Elect of the American College of Surgeons during the organization’s recent annual business meeting of members. The First Vice-President-Elect, Tyler G. Hughes, MD, FACS, and Second...
Shorter Course of Hypofractionated Radiation Therapy Yields Comparable Results to Conventional Radiotherapy for Patients With Nonmetastatic Soft-Tissue Sarcoma
Patients with nonmetastatic soft-tissue sarcoma who need preoperative radiation therapy can safely receive hypofractionated treatment for 3 weeks instead of 5 weeks, with comparable tumor control and no increased risk of major complications in wound healing, according to a new study published by...
Some Head and Neck Cancer Survivors May Be at Greater Risk for Long-Term Gastrostomy Tube Use
A small subset of patients who have undergone treatment for head and neck cancer may require a gastrostomy tube many years into survivorship, according to a new study published by Galloway et al in the International Journal of Radiation Oncology, Biology, and Physics. The findings were also...
FDA Approves Cemiplimab-rwlc in Combination With Platinum-Based Chemotherapy for NSCLC
On November 8, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo) in combination with platinum-based chemotherapy for adult patients with advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations. Study 16113 Efficacy was...
NCI-MATCH Trial: Ipatasertib Shows Signs of Effectiveness in Patients With AKT1 E17K–Mutant Solid Tumors
In the NCI-MATCH trial, which matches new treatments to patients with cancer based on the genetic makeup of their tumors, 22% of patients with AKT1 E17K–mutant metastatic tumors treated with the AKT inhibitor ipatasertib saw their tumors shrink, according to a novel study published by Kalinksy et...
Phase I Trial Shows Experimental Mini-Protein May Be Able to Inhibit the Cancer-Driving MYC Gene
Researchers have found that a new drug may be able to target—and for the first time, inhibit—the function of the MYC gene. Until now, no other drug has been able to do this safely and effectively, according to findings from a phase I clinical trial published by Garralda et al in the European...
Jonathan E. Rosenberg, MD, on Urothelial Cancer: Results From EV-103, Cohort K on Enfortumab Vedotin and Pembrolizumab
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses recent findings on the safety and antitumor activity of enfortumab vedotin-ejfv given intravenously as monotherapy or in combination with pembrolizumab to previously untreated cisplatin-ineligible patients with locally...
Robert J. Motzer, MD, on Renal Cell Carcinoma: New Results With Nivolumab and Ipilimumab
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse...
Repotrectinib for ROS1-Positive NSCLC Examined in Phase I/II TRIDENT-1 Trial
Early trials of the targeted oral drug repotrectinib discovered that it may help treat patients with a certain type of non–small cell lung cancer (NSCLC), according to a new study published by Cho et al in the European Journal of Cancer. The results of the TRIDENT-1 trial—presented at the 34th...
Preliminary Results From ARROS-1 Phase I Clinical Trial Suggest That NVL-520 May Be Well Tolerated and Active in NSCLC
Preliminary data from a phase I clinical trial of the ROS1 inhibitor NVL-520 to treat patients with non–small cell lung cancer (NSCLC) and other solid tumors suggested that it may have the potential to both halt tumor growth by inhibiting a cancer-causing gene change and reach cancer cells within...
Small Study of Experimental Drug to Treat Liver Cancer Shows Evidence of Activity With Manageable Side Effects
A new drug designed to inhibit an enzyme that plays a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer and up to three lines of previous unsuccessful treatment, according to a new study published by Reig et al ...
Cell-Free DNA Profiling in Patients With Advanced Cancers May Lead to Early Detection of Myeloid Malignancies
Researchers have found that an incidental finding of clonal hematopoiesis in liquid biopsies can be used to trigger hematologic tests to assess the risk of developing myeloid malignancies, according to a new study published by Tagliamento et al in the European Journal of Cancer. The findings were...
Sequential Dosing of Olaparib and Adavosertib in Patients With Advanced Tumors
Olaparib and adavosertib can be safely used to treat patients with cancers that are driven by certain mutations occurring in response to DNA damage if they are given in sequence rather than concurrently, according to a novel study published by Yap et al in the European Journal of Cancer. The...
Researchers Identify Specific Mutations in the BRAF Gene That May Affect Response to Treatment and Survival in Adult Brain Cancers
Researchers have identified a range of genetic mutations in gliomas that may help them understand how different mutations in the BRAF gene interact with other gene mutations—and which ones are more susceptible to targeted treatments in adults—according to a new study published by Schreck et al in...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer
Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head and neck squamous cell carcinoma, but favorable numerical trends were demonstrated, according to...
Expert Point of View: Robin Kate Kelley, MD
Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main take-away is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to ...
Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma: LEAP-002 Fails to Meet Co-primary Endpoints
The highly anticipated final analysis of the phase III LEAP-002 trial failed to meet expectations, as first-line treatment with lenvatinib plus pembrolizumab did not significantly improve outcomes in unresectable advanced hepatocellular carcinoma. Both progression-free survival and overall survival ...
FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms
The U.S. Food and Drug Administration (FDA) has approved cobimetinib (Cotellic), an oral inhibitor of MEK1 and MEK2, for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms. These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and...
Expert Point of View: Mary O’Brien, MD
Formal discussant Mary O’Brien, MD, Head of the Lung Unit, the Royal Marsden Hospital, NHS Foundation Trust, London, commented on the POSEIDON trial. “The POSEIDON trial is the largest data set we have on KRAS-mutated [non–small cell lung cancer], with a positive signal in picking up some patients...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
Expert Point of View: Natasha Leighl, MD
“CodeBreaK 200 clearly establishes sotorasib as the new standard of care, replacing docetaxel as second- or third-line therapy for advanced KRAS G12C–mutated lung cancer,” stated invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto. “Sotorasib improved...
Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC?
The KRAS G12C inhibitor sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of disease progression or death by 34% compared with standard second-line docetaxel for patients with previously treated non–small cell lung cancer (NSCLC) and KRAS G12C mutations....
Expert Point of View: Sanjay Popat, FRCP, PhD
“Adjuvant osimertinib has been adopted widespread as a standard of care as a result of the primary results of ADAURA,” said formal discussant Sanjay Popat, FRCP, PhD, medical oncologist and lung specialist at the Royal Marsden Hospital, NHS Foundation Trust, London. “We have more granularity about ...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Andrea McKee, MD, and Brady McKee, MD, Honored With the James L. Mulshine, MD, National Leadership Award for Ensuring Equitable Access to High-Quality Lung Cancer Screenings
Andrea McKee, MD, and the late Brady McKee, MD, will be honored with the James L. Mulshine, MD, National Leadership Award on Thursday, November 3, at the Prevent Cancer Foundation’s 19th annual Quantitative Imaging Workshop. The annual Mulshine Award is given to an individual or individuals who has ...
Researchers Discover Differences in Response to Pembrolizumab Among Patients With Endometrial Cancer
Researchers discovered a differential clinical response to pembrolizumab in patients with Lynch-like (mutated) vs methylated microsatellite instability–high endometrial cancer, outlining characteristics of patients who may derive benefit from immune checkpoint blockade antibodies, according to new...
Legal and Ethical Use of Complementary and Alternative Medicine Interventions in Oncology
In addition to, or instead of, receiving therapies that are the standard of care, patients with cancer sometimes request to receive complementary (therapies used in conjunction with standard cancer treatment) and alternative (nonstandard treatments used in place of standard cancer treatment)...
Neoadjuvant Immunotherapy With Relatlimab and Nivolumab in Stage III Melanoma
The combination of immune checkpoint inhibitors relatlimab and nivolumab for patients with stage III melanoma given before surgery was safe and completely cleared all viable tumor in 57% of patients in a phase II study, according to findings published by Amaria et al in Nature. In addition to...
Can Genetic Mutations Impact Radiation Sensitivity?
A new study identified both common and rare genetic mutations that may impact radiation resistance and sensitivity, an important step toward providing more individualized and effective radiotherapy for patients with cancer, according to findings published by Gopal et al in Clinical Cancer ...
Minority Patients Face Longer Waits for Non–Small Cell Lung Cancer Treatment
A new study has revealed significant racial disparities in how quickly minority patients with non–small cell lung cancer receive radiation therapy compared with their White counterparts, according to findings published by Rekulapelli et al in Health Equity. Researchers reviewed data from more than...
New Cervical Screening Test Could Predict Cell Changes Years Before They Occur
Researchers have developed a new swab test that can identify origins of potentially dangerous cervical cell changes up to 4 years before they happen, according to a new study published by Barrett et al in Genome Medicine. Scientists found that the new cervical screening method was more sensitive...
Analysis of Radiotherapy and Breast Cancer Recurrence in the RxPONDER Trial
Do patients with breast cancer and a low 21-gene recurrence score need regional node irradiation to reduce their risk of locoregional recurrence? An analysis of RxPONDER trial data suggests only a randomized clinical trial devoted to this question can provide a decisive answer. An analysis of data...
Multimodal Artificial Intelligence Models May Offer an Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer
NRG Oncology investigators analyzed clinical and digital histopathology data from five phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multimodal artificial intelligence models (MMAI) that could outperform the National Comprehensive Cancer...
2022 Annual Report to the Nation on the Status of Cancer Released
Overall cancer death rates continued to decline among men, women, children, adolescents, and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer...
AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO have released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The...
3-Week Course of Radiotherapy With Concurrent Radiation Boost Found to Be Safe and Effective for Patients With Early-Stage Breast Cancer and Elevated Risk of Recurrence
A 3-week course of radiation therapy is as safe and effective as 4 to 6 weeks of treatment for patients with early-stage breast cancer who have a higher risk of having their tumors recur, results of a randomized phase III clinical trial show. Delivering fewer, but higher, doses of radiation...
EXTEND Trial: Metastasis-Directed Radiation Therapy Plus Hormone Therapy May Improve Progression-Free Survival in Patients With Advanced Prostate Cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were...
Response-Adapted Ultra–Low Dose Radiation Achieves Complete Response in Majority of Patients With Orbital Indolent B-Cell Lymphomas
Using a novel response-adapted ultra–low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphomas. Results were presented by Pinnix et al at the 2022 American Society...
Sexual Side Effects of Cancer Treatment Often Unaddressed With Female Patients
A new study has found that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs. Among patients receiving brachytherapy for prostate or cervical cancer at a high-volume cancer...
Medical Physicist Consults May Help Reduce Patient Anxiety and Increase Satisfaction With Radiation Care
Meeting with a medical physicist who can explain how radiation therapy is planned and delivered may reduce patient anxiety and increase patient satisfaction throughout the treatment process, according to a new study published by Burmeister et al in the International Journal of Radiation Oncology •...
FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma
On October 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four...
YES Oklahoma Project Created to Improve Representation of Native Americans in Cancer Research
The National Cancer Institute of the National Institutes of Health (NIH) has awarded the University of Oklahoma (OU) an expected $2 million over 5 years to develop a program to improve representation of Oklahoma Native American students in biomedical and cancer research. “American Indian...
Incarceration May Be Associated With Higher Cancer Mortality, Yale Study Shows
New research from Yale Cancer Center reveals a higher risk of cancer mortality in incarcerated adults, as well as among those diagnosed with cancer in the first year after release from prison. The findings were published in the journal PLoS One.1 “Cancer is the leading cause of death among people...
FDA Approves Tremelimumab Plus Durvalumab for Adult Patients With Unresectable HCC
On October 21, the U.S. Food and Drug Administration (FDA) approved tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the...
Prophylactic Radiation for Asymptomatic Bone Metastases May Reduce Pain and Extend Survival
Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial were...
PCS5 Trial: Long-Term Outcomes of Moderately Shortened Radiation Course for High-Risk Prostate Cancer
A randomized study has confirmed that patients with high-risk prostate cancer can be treated with 5 vs 8 weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk...
Small First-in-Human Trial Investigates FLASH Proton Radiotherapy for Patients With Bone Metastases
FLASH radiation treatment—which delivers therapeutic doses of radiation in a fraction of a second—may be a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests. The technology, previously tested in animals, was shown to be as...
Adding SBRT to Sorafenib May Improve Survival and Time to Disease Progression in Patients With Advanced HCC
Adding stereotactic body radiation therapy (SBRT) to systemic therapy with sorafenib for patients with advanced hepatocellular carcinoma (HCC) may extend overall survival and delay tumor progression without compromising patients’ quality of life, findings from the randomized phase III NRG...
